KOSPIHolding Companies003090

Daewoong

₩15,700▼ 3.74%2026-11-18 close
Market Cap
₩912.8B
Turnover
₩1B
Volume
60K
Shares out.
58.1M
PER
3.9×
PBR
0.5×
EPS
₩4,121
Dividend Yield
1.24%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩200 per share · Prices as of the 2026-11-18 close

01

Report overview

Daewoong: A Holding Company Tied to Daewoong Pharma's Results

Daewoong is a holding company that owns 52.29% of Daewoong Pharma, and its operating profit rose for three straight quarters through Q3 2026 while net profit attributable to controlling shareholders fell over the same period, making that divergence the central question.

  1. 1

    Operating profit reached KRW 88.8 billion in Q3 2026, up 10.3% from a year earlier, while net profit attributable to controlling shareholders was KRW 32 billion, down 20.4%.

  2. 2

    Daewoong Pharma's provisional separate-basis Q3 2026 results, disclosed on November 4, 2026, showed Nabota export sales of KRW 106.8 billion, up 127.9% from a year earlier, which the company described as a record.

  3. 3

    KB Securities researcher Shin Ji-hoon said in reports dated November 4, 2026 that Nabota shipments to the U.S. were concentrated in Q3 and that a shipment gap could continue from Q4.

  4. 4

    The debt ratio stood at 82.9% at the end of 2025, up from 64.2% in 2023, while operating cash flow rose to KRW 257.6 billion in 2025 from KRW 162.4 billion in 2024.

  5. 5

    The stock trades below 1x price-to-book, so the relationship between the value of its subsidiary stakes and the holding company's share price is central to valuation.

02

Business structure

Daewoong was founded in 1961 and converted into a holding company in 2002, and it had 35 consolidated subsidiaries as of 2026. Its core subsidiary is Daewoong Pharma, in which Daewoong holds a 52.29% stake according to the business report filed on March 18, 2026.

Daewoong Pharma runs the botulinum toxin Nabota, an acid-reflux treatment, the OTC liver remedy Urso, an OTC business and a digital healthcare business. A separate subsidiary handles raw materials and finished drugs, and another handles synthetic and biologic drug R&D, manufacturing and sales.

In provisional separate-basis results for Q3 2026, disclosed on November 4, 2026, Nabota export sales were KRW 106.8 billion, up 127.9% from a year earlier, and exports made up most of the KRW 116.3 billion combined domestic and overseas Nabota sales.

A U.S. partner reportedly stocked up ahead of tariffs taking effect in September, which is cited as the main driver. OTC sales rose 21% and digital healthcare sales rose 40% from a year earlier.

The Pexuclu co-marketing contract with Chong Kun Dang ended on August 31, and the 20mg product moved to sole sales, while Pexuclu sales in Q3 fell 84.5% year on year. The public filings do not break out revenue by segment, so the subsidiary-level mix must be checked in periodic reports.

The business is best understood through its subsidiary portfolio and the value of its stakes rather than through any single product.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩542.2B₩80.5B14.9%
2025Q4₩516.3B₩34.8B6.7%
2026Q1₩492.7B₩47.8B9.7%
2026Q2₩570.8B₩76.6B13.4%
2026Q3₩594.1B₩88.8B15.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩1.7T₩207.3B₩102.6B12.2%12.4%68.7%
2023₩1.8T₩195.6B₩152.7B10.8%16.3%64.2%
2024₩1.9T₩281.9B₩57.9B14.6%5.8%81.1%
2025₩2.1T₩261.8B₩175.1B12.7%14.9%82.9%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Based on the filed figures, annual revenue rose from KRW 1.7 trillion in 2022 to KRW 1.81 trillion in 2023 (up 6.9%), KRW 1.94 trillion in 2024 (up 6.8%) and KRW 2.07 trillion in 2025 (up 6.8%), marking three straight years of growth from 2023 through 2025.

Operating profit was KRW 207.3 billion in 2022, KRW 195.6 billion in 2023 (down 5.7%), KRW 281.9 billion in 2024 (up 44.1%) and KRW 261.8 billion in 2025 (down 7.1%). Revenue kept rising while operating profit fell after its 2024 peak, and the operating margin slid from 14.6% in 2024 to 12.7% in 2025.

Net profit attributable to controlling shareholders was KRW 102.6 billion in 2022, KRW 152.7 billion in 2023, KRW 57.9 billion in 2024 (down 62.1%) and KRW 175.1 billion in 2025 (up 202.4%), so earnings recovered in 2025 from the 2024 low.

Net profit including non-controlling interests was KRW 68.9 billion in 2024 and KRW 227.9 billion in 2025, and the gap between that figure and the controlling-shareholder figure in 2025 reflects non-controlling interests.

Quarterly operating profit bottomed at KRW 34.8 billion in Q4 2025, down 56.8% from the prior quarter, and then rose for three consecutive quarters to KRW 47.8 billion in Q1 2026, KRW 76.6 billion in Q2 and KRW 88.8 billion in Q3.

Revenue fell to KRW 492.7 billion in Q1 2026 and then rose to KRW 570.8 billion in Q2 and KRW 594.1 billion in Q3, two straight quarters of growth. In Q3 2026, operating profit grew 10.3% year on year, faster than the 9.6% revenue growth.

Net profit attributable to controlling shareholders peaked at KRW 69.9 billion in Q4 2025 and then fell for three consecutive quarters to KRW 35.3 billion, KRW 34.1 billion and KRW 32 billion in Q3 2026. The sum of the last four quarters of controlling-shareholder net profit is KRW 171.2 billion.

At the end of 2025, equity totaled KRW 1.77 trillion, of which the controlling-shareholder portion was KRW 1.18 trillion, and total liabilities were KRW 1.46 trillion. The debt ratio rose from 64.2% in 2023 to 81.1% in 2024 and 82.9% in 2025.

Operating cash flow was KRW 257.6 billion in 2025, up from KRW 162.4 billion in 2024. Separately, Daewoong Pharma's provisional separate-basis Q3 2026 operating profit was KRW 76.8 billion, up 43.5% year on year (disclosed November 4, 2026), which is a subsidiary figure and not Daewoong's own result.

05

Industry analysis

Daewoong's end market is effectively the pharmaceutical and biotech cycle its subsidiaries operate in. The holding company's earnings move with Daewoong Pharma's operating performance and the value of its subsidiary stakes.

The strength in Q3 2026 Nabota exports is attributed to a U.S. partner stocking up before tariffs took effect in September, which points to shipment timing rather than necessarily a durable jump in demand. Whether overseas demand is stable on a quarterly average basis therefore needs further checking.

Pexuclu moved to direct sales after its co-marketing period ended, creating a revenue gap, and Q3 prescription drug sales fell 3.1% year on year to KRW 218.4 billion at the separate-basis level, per November 2026 reports.

Daewoong Pharma is expanding OTC and digital healthcare to broaden its revenue base beyond prescription drugs. Holding-company shares often trade at a discount to the market value of their subsidiary stakes, so subsidiary results pass through to the parent's share price only indirectly.

Through Daewoong Pharma, Daewoong also holds a stake in the U.S.-listed biotech AEON Biopharma, which extends its portfolio beyond pharmaceutical sales. Comparisons with other listed holding companies are limited because portfolio and ownership structures differ from company to company.

06

Outlook

The nearest checkpoint is Q4, when a gap in Nabota shipments to the U.S. could emerge after the Q3 shipments were concentrated, according to securities analysts.

Pexuclu 10mg and 40mg will be sold solely by Daewoong Pharma from December 1, 2026, and how quickly revenue recovers after the switch to direct sales is the next item to track. Daewoong Pharma attributed its Q3 gains to export growth as well as OTC and digital healthcare expansion.

Separately, reports in November 2026 said some securities firms lowered their target prices for Daewoong Pharma after results and cut their 2026 and 2027 earnings estimates.

On the asset side, Daewoong Pharma held 30.5% of AEON Biopharma as of November 9, 2026, and full exercise of its warrants could lift that stake to about 37.1%. Daewoong's combined stake, including its direct holding, was 30.6%.

Reports in November 2026 also said Daewoong Pharma is exploring a sale of control of a new-drug development subsidiary. The 2026 business report is due by March 31, 2027, and it will make full-year 2026 results official in the filed figures.

07

Valuation

PER
3.9×
PBR
0.5×
ROE
14.6%
EPS
₩4,121
BPS
₩30,117
Dividend per share
₩200

Daewoong's share price reflects a holding-company structure centered on its stake in Daewoong Pharma. The price-to-book ratio is below 1x, which means the market values the company below its book equity.

Holding companies often trade at a discount to the market value of their subsidiary stakes, and that gap is a structural feature here. On earnings, the most recent four quarters of controlling-shareholder net profit total KRW 171.2 billion, and this can be read against the current market capitalization.

Controlling-shareholder profit recovered in 2025 from the 2024 low, but operating profit has grown while controlling-shareholder profit has fallen in 2026, so the quality of earnings needs to be read alongside both measures.

The debt ratio rose from 64.2% in 2023 to 82.9% in 2025, so the capital structure has shifted and should be considered when reading the price-to-book ratio. Dividend yield moves with the share price, so the direction of payout relative to earnings matters more than the absolute level. Valuation multiples reflect both the holding structure and subsidiary earnings volatility.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Nabota exports and margin improvement

Daewoong Pharma's provisional Q3 2026 results showed Nabota export sales of KRW 106.8 billion, up 127.9% year on year, which the company called a record. The company said a larger share of higher-margin products, centered on Nabota, contributed to better profitability. Daewoong's operating profit has risen for three consecutive quarters from Q1 through Q3 2026.

2025 earnings recovery and cash generation

Net profit attributable to controlling shareholders rose from KRW 57.9 billion in 2024 to KRW 175.1 billion in 2025, a 202.4% increase that recovered from the low. Operating cash flow was KRW 257.6 billion in 2025, up from KRW 162.4 billion in 2024. Operating cash flow has stayed above KRW 100 billion each year since 2022.

AEON stake and warrant optionality

Daewoong Pharma held 30.5% of U.S.-listed AEON Biopharma as of November 9, 2026. Exercising its warrant for up to 8 million additional shares could raise the stake to about 37.1%. Daewoong's combined stake is 30.6%.

09

Bear factors

Concern over a Nabota shipment gap

KB Securities researcher Shin Ji-hoon said in reports dated November 4, 2026 that after Nabota U.S. shipments were concentrated in Q2 and Q3, a shipment gap is expected from Q4. The same reports named the partner's future guidance and shipment schedule as the key to earnings. If much of Q3 reflected shipment timing, quarterly results after Q4 could come in lower.

Gap from Pexuclu's switch to direct sales

Pexuclu's 20mg product moved to sole sales after the co-marketing contract ended, and Q3 Pexuclu sales fell 84.5% year on year. The 10mg and 40mg products will also be sold solely by Daewoong Pharma from December 1, 2026. If the pace of revenue recovery under direct sales is slow, the gap in subsidiary earnings could last longer.

Diverging profit trends and higher debt

Net profit attributable to controlling shareholders has fallen for three consecutive quarters from Q1 through Q3 2026, reaching KRW 32 billion in Q3, down 20.4% year on year. The operating margin fell from 14.6% in 2024 to 12.7% in 2025.

The debt ratio rose to 82.9% at the end of 2025 from 64.2% in 2023, so financial burden could grow if profits remain volatile.

10

Risk factors

Governance and related-party transactions

A December 2025 report said the Daewoong family holds stakes in 17 unlisted family companies, and questions have been raised about work being steered to them. As a holding company owning 52.29% of Daewoong Pharma, Daewoong's internal transactions with subsidiaries can affect how its reported results are read. Scale and terms of related-party transactions should be checked in the notes to periodic reports.

Changes in subsidiary ownership

Reports in November 2026 said Daewoong Pharma is pursuing a sale of control of a new-drug development subsidiary. A sale would change the subsidiary's earnings and the value of the stake. Daewoong Pharma's stake in AEON Biopharma will also change depending on whether the warrants are exercised.

Tariffs and reliance on export demand

The strength in Nabota exports is attributed to a U.S. partner stocking up before tariffs took effect in September. As export exposure rises, changes in tariffs and trade policy could move quarterly results sharply. If the Q3 export growth reflected shipment timing, the stability of underlying demand needs further checking.

11

What to watch next

  1. December 1, 2026

    Pexuclu 10mg and 40mg move to sole sales by Daewoong Pharma on this date. The pace of revenue recovery after the switch to direct sales is the next checkpoint for subsidiary earnings.

  2. Q4 2026

    This is when to check how far Nabota U.S. shipments fall after the Q3 concentration. If a shipment gap appears as analysts expect, the direction of Q4 net profit attributable to controlling shareholders could change.

  3. Timing not set (following November 2026 reports)

    Outcomes of the sale-of-control process at the new-drug development subsidiary and any exercise of the AEON Biopharma warrants. A change in subsidiary ownership would alter the value and percentage of Daewoong's holdings.

  4. By March 31, 2027

    This is the filing deadline for the 2026 business report. It will fix full-year 2026 revenue, operating profit, controlling-shareholder net profit, the debt ratio and operating cash flow as filed results.

12

Overall view

Daewoong is a holding company that owns 52.29% of Daewoong Pharma, and its results move with the earnings and stake values of its subsidiaries. Filed 2025 figures show revenue rising for three straight years and controlling-shareholder net profit recovering from the 2024 low.

In quarterly results through 2026, operating profit has risen for three consecutive quarters while controlling-shareholder net profit has fallen over the same period.

Daewoong Pharma's provisional Q3 results showed a sharp rise in Nabota exports, but if a shipment gap appears from Q4 as analysts expect, the direction of quarterly results could change. The Pexuclu switch to direct sales and Nabota shipment flows are the business checkpoints to watch next.

On the balance sheet, the debt ratio rose from 64.2% in 2023 to 82.9% in 2025, so changes in the capital structure need to be read alongside earnings.

The stock trades below 1x price-to-book, which makes the link between asset value and share price central to valuation, and changes in subsidiary ownership and the AEON stake are further items to track. The 2026 business report, due by March 31, 2027, will set full-year 2026 results in filed form.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 18 more articles and sources
  1. comp.fnguide.com
  2. medicopharma.co.kr
  3. datatooza.com
  4. samsungpop.com
  5. newstopkorea.com
  6. m.sedaily.com
  7. m.news.nate.com
  8. comp.wisereport.co.kr
  9. kind.krx.co.kr
  10. saramin.co.kr
  11. huffingtonpost.kr
  12. insight.co.kr
  13. viva100.com
  14. daily.hankooki.com
  15. view.asiae.co.kr
  16. m.news.nate.com
  17. kpanews.co.kr
  18. news.mtn.co.kr

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis